Last update Jan. 13, 2024

C21H39N7O12

Compatible

Safe substance and/or breastfeeding is the best option.

Streptomycin is an aminoglycoside antibiotic indicated to treat nontuberculous mycobacterial infections, multidrug-resistant tuberculosis and other nontuberculous infections. Intramuscular administration.

It is excreted in breast milk in clinically insignificant amounts. (Algharably 2023, Tran 1998, Snider 1984, Knowles 1973)

Its very low oral bioavailability prevents passage into infant plasma from ingested breast milk, except in premature infants and immediate neonatal period where there may be increased intestinal permeability.

List of essential drugs WHO: compatible with breastfeeding (WHO-UNICEF 2002). American Academy of Pediatrics: medication generally compatible with breastfeeding. (AAP 2001)

Although rare, the possibility of transient gastroenteritis due to altered intestinal flora in infants whose mothers take antibiotics should be taken into account.

Alternatives

We do not have alternatives for C21H39N7O12 since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

C21H39N7O12 is Streptomycin in Molecular formula.

Is written in other languages:

C21H39N7O12 is also known as

Groups

C21H39N7O12 belongs to these groups or families:

Tradenames

Main tradenames from several countries containing C21H39N7O12 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 582 daltons
Protein Binding 33 %
pKa 11.09 -
Tmax 1 - 2 hours
T½ 2.5 hours
M/P ratio 0.12 - 1 -
Theoretical Dose 0.2 mg/Kg/d
Relative Dose 0.3 - 0.6 %
Ped.Relat.Dose 0.5 %

References

  1. Algharably EA, Kreutz R, Gundert-Remy U. Infant Exposure to Antituberculosis Drugs via Breast Milk and Assessment of Potential Adverse Effects in Breastfed Infants: Critical Review of Data. Pharmaceutics. 2023 Apr 13;15(4). pii: 1228. Abstract Full text (link to original source)
  2. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)
  3. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  4. Tran JH, Montakantikul P. The safety of antituberculosis medications during breastfeeding. J Hum Lact. 1998 Dec;14(4):337-40. Review. Abstract
  5. Snider DE Jr, Powell KE. Should women taking antituberculosis drugs breast-feed? Arch Intern Med. 1984 Abstract
  6. Knowles JA. Effects on the infant of drug therapy in nursing mothers. Drug Ther (NY). 1973 Abstract

Total visits

259

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM